Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CHMP 2019

- PMLiVE

Researchers uncover promising treatment approach for inherited breast cancer

The study evaluated chemotherapy followed by a targeted cancer drug in patients before surgery

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE to treat advanced breast cancer

BRCA1 and BRCA2 mutations are responsible for 52% and 32% of hereditary breast cancer cases, respectively

- PMLiVE

Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer

Ovarian cancer is the seventh most common cancer in women globally

European Federation of Clinical Chemistry and Laboratory Medicine hosts EU Lab Day

Europe Celebrates the Vital Role of Laboratory Medicine and its Contribution to European Health, Security and Future Wellbeing

The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) will be hosting European Laboratory Day, on November 05th 2024. This annual event celebrates the contributions of laboratory medicine professionals...

EatMoreFruit

- PMLiVE

AstraZeneca’s Imfinzi/Lynparza regimens granted EC approval to treat endometrial cancer

Almost 125,000 new cases of endometrial cancer were diagnosed in Europe in 2022

- PMLiVE

ICR study reveals Lynparza could treat more advanced prostate cancer patients

Up to 30% of men living with the advanced disease have tumours that contain defects in repairing DNA

- PMLiVE

AstraZeneca’s Imfinzi/Lynparza regimen recommended by CHMP to treat endometrial cancer

Almost 125,000 cases of endometrial cancer were diagnosed in Europe in 2022

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi and Lynparza in endometrial cancer

The incidence of endometrial cancer is expected to increase by approximately 61% in 2050

- PMLiVE

AstraZeneca/Merck’s Lynparza recommended by NICE for advanced prostate cancer

The combination therapy has been recommended for patients regardless of biomarker status

- PMLiVE

AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer

Approximately 7,400 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Market access and reimbursement in key European markets

An introductory guide to European market access and reimbursement stakeholders and processes in France, Great Britain, Germany, Italy and Spain.

Petauri Evidence

- PMLiVE

AstraZeneca latest to sue US government over Medicare drug price negotiation plan

The programme already faces court challenges from drugmakers and industry groups

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links